Letters

Hypertrophic cardiomyopathy: Combination of β blockers and verapamil may be risky

BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7558.97 (Published 06 July 2006) Cite this as: BMJ 2006;333:97
  1. Javier Borja, drug safety manager (fv-borja@uriach.com),
  2. Iñaki Izquierdo, head, clinical development,
  3. Josep Guindo, staff cardiologist
  1. J Uriach y Compañía, SA Av Camí Reial, 51-57, 08184 Palau-solità i Plegamans, Barcelona, Spain
  2. J Uriach y Compañía, SA Av Camí Reial, 51-57, 08184 Palau-solità i Plegamans, Barcelona, Spain
  3. Coronary Care Unit, Avinguda Sant Antoni María Claret, 167, 08025 Barcelona

    EDITOR—Spirito and Autore recommend β blockers or verapamil, or the two drugs combined, to control heart rate in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation. To recommend the combination …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe